We first measured the expression of surface markers CD4, CD25, and TNFR2 on peripheral blood mononuclear cells (PBMCs) to evaluate the percentage of TNFR2+Tregs in the peripheral blood of patients with CC, patients with CIN III, and in healthy controls. This evidence concerns the gene TNFRSF1B and uterine cervix carcinoma in situ.